v3.23.2
Overview and Basis of Presentation (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2022
Dec. 31, 2022
Jun. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Gain on sale of contingent payments       $ 127.9  
Cash, cash equivalents, and marketable securities         $ 946.9
2010 Agreement          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Milestone payment for achievement of specified ex-U.S. commercial milestone event $ 25.0        
TIBSOVO | UNITED STATES          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Earn-out revenue for royalties   $ 2.7 $ 5.4    
Discontinued Operations, Disposed of by Sale | Agios Oncology Business          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Cash proceeds 1,800.0        
Contingent milestone payment $ 200.0        
Discontinued Operations, Disposed of by Sale | Agios Oncology Business | TIBSOVO | UNITED STATES          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Contingent royalty payment 5.00%        
Discontinued Operations, Disposed of by Sale | Agios Oncology Business | Vorasidenib | UNITED STATES          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Contingent royalty payment 15.00%